Skip to main content

Advertisement

SpringerLink
Log in

New vitamin D analogues for osteodystrophy in chronic kidney disease

  • Editorial Commentary
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Vitamin D therapy for patients with chronic kidney disease has until recently comprised alfacalcidol or calcitriol, both of which effectively attenuate secondary hyperparathyroidism and the target organ consequences thereof. Unfortunately, both these agents also have significant calcaemic and phosphataemic actions leading to frequent episodes of hypercalcaemia, hyperphosphataemia and an increase in the CaxP product. It is likely that these in turn have adverse effects on cardiovascular and survival outcomes by promoting soft tissue and vascular calcification. These drawbacks have fuelled a search for vitamin D compounds with a wider therapeutic window. Experimentally, some of these have exhibited remarkable dissociation between their ability to suppress parathyroid hormone (PTH) and concomitant calcaemic actions. In the case of 22-oxacalcitriol, the calcaemic potency relative to parathyroid suppression is 100th of that of calcitriol. 22-oxacalcitriol, with paricalcitol and doxercalciferol, are now widely used. Clinical studies of these agents, while confirming efficacy that is at least as good as alfacalcidol/calcitriol, have not consistently shown benefit in head to head comparison. Experience with these agents in the paediatric arena is very limited. One placebo-controlled study has now been completed in children—paricalcitol appeared effective and well tolerated. Calcimimetics, which simultaneously lower PTH, calcium and the CaxP product are about to enter the clinical arena—early studies in adults look promising, although they will need careful evaluation in children. These two therapies are likely to be additive and will probably complement one another effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abe J, Takita Y, Nakano T, Miyaura C, Suda T, Nishii Y (1989) A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124:2645–2647

    CAS  PubMed  Google Scholar 

  2. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E (1989) The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728–732

    CAS  PubMed  Google Scholar 

  3. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483

    CAS  PubMed  Google Scholar 

  4. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105

    PubMed  Google Scholar 

  5. Coburn JW, Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Knutson JC, Bishop CW (1996) 1 alpha-Hydroxy-vitamin D2: a new look at an ‘old’ compound. Nephrol Dial Transplant 11 [Suppl 3]:153–157

  6. Knutson JC, LeVan LW, Valliere CR, Bishop CW (1997) Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol. Biochem Pharmacol 53:829–837

    Article  CAS  PubMed  Google Scholar 

  7. Mawer EB, Jones G, Davies M, Still PE, Byford V, Schroeder NJ, Makin HL, Bishop CW, Knutson JC (1998) Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrinol Metab 83:2156–2166

    Article  CAS  PubMed  Google Scholar 

  8. Coburn JW (1990) Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int [Suppl] 29:S54–S61

    Google Scholar 

  9. Mazess RB, Elangovan L (2003) A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin Nephrol 59:319–325

    CAS  PubMed  Google Scholar 

  10. Steddon SJ, Schroeder NJ, Cunningham J (2001) Vitamin D analogues: how do they differ and what is their clinical role? Nephrol Dial Transplant 16:1965–1967

    Article  CAS  PubMed  Google Scholar 

  11. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, Selznick SH, Whitfield GK (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 154 [Suppl]:S57–S73

  12. Haussler MR, Jurutka PW, Hsieh JC, Thompson PD, Selznick SH, Haussler CA, Whitfield GK (1995) New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Bone 17:33S–38S

    Article  CAS  PubMed  Google Scholar 

  13. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349

    Google Scholar 

  14. Boyan BD, Bonewald LF, Sylvia VL, Nemere I, Larsson D, Norman AW, Rosser J, Dean DD, Schwartz Z (2002) Evidence for distinct membrane receptors for 1 alpha,25-(OH)(2)D(3) and 24R,25-(OH)(2)D(3) in osteoblasts. Steroids 67:235–246

    Article  CAS  PubMed  Google Scholar 

  15. Nemere I, Yazzie-Atkinson D, Johns DO, Larsson D (2002) Biochemical characterization and purification of a binding protein for 24,25-dihydroxyvitamin D3 from chick intestine. J Endocrinol 172:211–219

    CAS  PubMed  Google Scholar 

  16. Bailie GR, Johnson CA (2002) Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial 15:352–357

    Article  PubMed  Google Scholar 

  17. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E (1993) The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133:1158–1164

    Article  CAS  PubMed  Google Scholar 

  18. Horst R, Prapong S, Reinhardt T, Koszewski N, Knutson J, Bishop C (2000) Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat. Biochem Pharmacol 60:701–708

    Article  CAS  PubMed  Google Scholar 

  19. MacDonald PN, Baudino TA, Tokumaru H, Dowd DR, Zhang C (2001) Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids 66:171–176

    Article  CAS  PubMed  Google Scholar 

  20. Issa LL, Leong GM, Sutherland RL, Eisman JA (2002) Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 17:879–890

    CAS  PubMed  Google Scholar 

  21. Schroeder NJ, Burrin JM, Noonan K, Makin HL, Cunningham J (2003) Effects of ‘non-calcaemic’ vitamin D analogues on 24-hydroxylase expression in MG-63 osteoblast-like cells. Nephron Physiol 94:62–73

    Article  Google Scholar 

  22. Brown AJ, Berkoben M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E (1992) Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells. Biochem Biophys Res Commun 189:759–764

    CAS  PubMed  Google Scholar 

  23. Slatopolsky E, Finch J, Ritter C, Takahashi F (1998) Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32:S40–S47

    CAS  PubMed  Google Scholar 

  24. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E (1996) Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 11 [Suppl] 3:121–124

    Google Scholar 

  25. Kinugasa E, Akizawa T, Takahashi J, Nabeshima K, Ogata H, Nakayama F, Ideura T (2002) Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 17 [Suppl] 10:20–27

    Google Scholar 

  26. Doi S, Yorioka N, Usui K, Shigemoto K, Harada S (2003) Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients. Intern Med 42:955–959

    CAS  PubMed  Google Scholar 

  27. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315–323

    CAS  PubMed  Google Scholar 

  28. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48–S54

    CAS  PubMed  Google Scholar 

  29. Cunningham J (1999) What is the optimal regimen for vitamin D? Kidney Int [Suppl] 73:S59–S64

    Google Scholar 

  30. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D (2001) Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38:S51–S56

    CAS  Google Scholar 

  31. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483–1490

    CAS  PubMed  Google Scholar 

  32. Kommala D, Benador N, Goldstein S, Pardes A, Mattingly S, Amdhal MG, L, Williams LA, Salusky I (2003) Paricalcitol (Zemplar) injection for the treatment of secondary hyperparathyroidism in pediatric hemodialysis patients. Proceedings of the American Society of Nephrology, San Diego

  33. Llach F, Qiu EA, Ross EA, Abboud H, Mere CC, Wojtak A, Hippensteel R, Williams LA, Block G (2003) Paricalcitol (Zemplar) capsule controls secondary hyperparathyroidism in chronic hemodialysis patients. Proceedings of the American Society of Nephrology, San Diego

  34. Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW (2000) Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36:550–561

    CAS  PubMed  Google Scholar 

  35. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456

    Article  CAS  PubMed  Google Scholar 

  36. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575–583

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, The Middlesex Hospital, University College London Hospitals, Mortimer Street, London W1N 8AA, UK

    John Cunningham

Authors
  1. John Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Cunningham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cunningham, J. New vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol 19, 705–708 (2004). https://doi.org/10.1007/s00467-004-1478-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1478-0

Keywords

Search

Navigation